阴性乳腺癌-话题@MedSci

#阴性乳腺癌#

226篇内容 | 3206人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2047924, encodeId=237b204e92424, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=SABCS 2014：Pembrolizumab使部分三阴性乳腺癌患者产生持续应答, objectType=article, longId=44049, objectId=e5794404941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5794404941, replyNumber=0, likeNumber=59, createdTime=2015-01-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5794404941, moduleTitle=SABCS 2014：Pembrolizumab使部分三阴性乳腺癌患者产生持续应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5794404941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047914, encodeId=1550204e91439, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益, objectType=article, longId=36094, objectId=bf553609449, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf553609449, replyNumber=0, likeNumber=74, createdTime=2014-07-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf553609449, moduleTitle=ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf553609449)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047916, encodeId=ecb1204e916e3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, objectType=article, longId=38348, objectId=af3d38348b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af3d38348b5, replyNumber=0, likeNumber=77, createdTime=2014-09-22, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af3d38348b5, moduleTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af3d38348b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047918, encodeId=3dd2204e9182b, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验), objectType=article, longId=40873, objectId=e833408e36f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e833408e36f, replyNumber=0, likeNumber=97, createdTime=2015-02-02, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e833408e36f, moduleTitle=ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e833408e36f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047920, encodeId=1c24204e9203e, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=“联合预测模型”为分类治疗三阴性乳腺癌导航, objectType=article, longId=41898, objectId=bede418983b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bede418983b, replyNumber=0, likeNumber=69, createdTime=2015-08-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bede418983b, moduleTitle=“联合预测模型”为分类治疗三阴性乳腺癌导航, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bede418983b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047907, encodeId=a90c204e9079f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Res：三阴性乳腺癌研究获进展, objectType=article, longId=28319, objectId=e2a72831999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2a72831999, replyNumber=0, likeNumber=84, createdTime=2014-04-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2a72831999, moduleTitle=Cancer Res：三阴性乳腺癌研究获进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2a72831999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047910, encodeId=a406204e91000, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Ann Surg Oncol：大部分淋巴结阴性乳腺癌可避免腋窝淋巴结摘除, objectType=article, longId=30504, objectId=e08030504e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e08030504e4, replyNumber=0, likeNumber=100, createdTime=2014-11-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e08030504e4, moduleTitle=Ann Surg Oncol：大部分淋巴结阴性乳腺癌可避免腋窝淋巴结摘除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e08030504e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047911, encodeId=7cd1204e91178, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Nature：同济大学参与发表三阴性乳腺癌全新结果, objectType=article, longId=32356, objectId=093932356f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=093932356f3, replyNumber=0, likeNumber=49, createdTime=2014-08-16, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=093932356f3, moduleTitle=Nature：同济大学参与发表三阴性乳腺癌全新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=093932356f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047908, encodeId=d19b204e908d1, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Ann Surg Oncol：大切缘手术不降低三阴性乳腺癌局部复发率, objectType=article, longId=28667, objectId=728e2866e93, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=728e2866e93, replyNumber=0, likeNumber=63, createdTime=2014-03-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=728e2866e93, moduleTitle=Ann Surg Oncol：大切缘手术不降低三阴性乳腺癌局部复发率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=728e2866e93)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047915, encodeId=dd05204e91574, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO 2014：gBRCA突变和家族史是三阴性乳腺癌pCR高的预测因素, objectType=article, longId=36100, objectId=89703610081, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89703610081, replyNumber=0, likeNumber=73, createdTime=2015-03-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89703610081, moduleTitle=ASCO 2014：gBRCA突变和家族史是三阴性乳腺癌pCR高的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89703610081)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047912, encodeId=1db7204e91260, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）, objectType=article, longId=35032, objectId=208c35032c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=208c35032c3, replyNumber=0, likeNumber=77, createdTime=2015-03-17, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=208c35032c3, moduleTitle=ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=208c35032c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047909, encodeId=37ef204e9092f, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=SABCS 2013：三阴性乳腺癌新辅助化疗获益, objectType=article, longId=28682, objectId=bebf28682da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bebf28682da, replyNumber=0, likeNumber=75, createdTime=2014-06-09, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bebf28682da, moduleTitle=SABCS 2013：三阴性乳腺癌新辅助化疗获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bebf28682da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047906, encodeId=2aca204e906e2, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JCO：西妥昔单抗联合顺铂可改善三阴性乳腺癌患者生存, objectType=article, longId=20829, objectId=33962082990, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33962082990, replyNumber=0, likeNumber=64, createdTime=2013-09-24, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33962082990, moduleTitle=JCO：西妥昔单抗联合顺铂可改善三阴性乳腺癌患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33962082990)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047904, encodeId=93fd204e904f3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞, objectType=article, longId=18292, objectId=0fad1829240, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fad1829240, replyNumber=0, likeNumber=67, createdTime=2013-09-12, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fad1829240, moduleTitle=Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fad1829240)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047905, encodeId=96ff204e905fe, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO 2013：三阴性乳腺癌患者中TNBC亚型可预测患者对治疗的应答率, objectType=article, longId=20247, objectId=9fde2024e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fde2024e0b, replyNumber=0, likeNumber=63, createdTime=2013-09-10, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fde2024e0b, moduleTitle=ASCO 2013：三阴性乳腺癌患者中TNBC亚型可预测患者对治疗的应答率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fde2024e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047902, encodeId=b268204e902e4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=PLoS ONE：肿瘤周围组织存在抑制三阴性乳腺癌转移物质, objectType=article, longId=9935, objectId=630499352f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=630499352f, replyNumber=0, likeNumber=116, createdTime=2013-02-13, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=630499352f, moduleTitle=PLoS ONE：肿瘤周围组织存在抑制三阴性乳腺癌转移物质, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=630499352f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047903, encodeId=6dd7204e90301, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征, objectType=article, longId=13939, objectId=f49713939ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f49713939ce, replyNumber=0, likeNumber=71, createdTime=2013-07-07, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f49713939ce, moduleTitle=Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f49713939ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047897, encodeId=bfcf204e897bc, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=NEJM：新辅助化疗和贝伐单抗治疗HER2-阴性乳腺癌, objectType=article, longId=3843, objectId=f46038438c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f46038438c, replyNumber=0, likeNumber=67, createdTime=2012-11-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f46038438c, moduleTitle=NEJM：新辅助化疗和贝伐单抗治疗HER2-阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f46038438c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047901, encodeId=e0db204e90123, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌：探索与进展, objectType=article, longId=5139, objectId=2c775139e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c775139e5, replyNumber=0, likeNumber=75, createdTime=2013-01-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c775139e5, moduleTitle=三阴性乳腺癌：探索与进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c775139e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2047900, encodeId=56e1204e90055, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=J. Exp. Med.：阻断CDK蛋白可导致三阴性乳腺癌萎缩, objectType=article, longId=4841, objectId=83d6484147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83d6484147, replyNumber=0, likeNumber=49, createdTime=2012-12-23, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83d6484147, moduleTitle=J. Exp. Med.：阻断CDK蛋白可导致三阴性乳腺癌萎缩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83d6484147)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阴性乳腺癌

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

SABCS 2014：Pembrolizumab使部分三阴性乳腺癌患者产生持续应答

2015-01-15

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益

2014-07-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）

2014-09-22

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ESMO 2014：吉西他滨联合顺铂(GP)或紫杉醇(GT)一线治疗复发或转移性三阴性乳腺癌获良好疗效(CBCSG006试验)

2015-02-02

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

“联合预测模型”为分类治疗三阴性乳腺癌导航

2015-08-04

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Res：三阴性乳腺癌研究获进展

2014-04-15

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Ann Surg Oncol：大部分淋巴结阴性乳腺癌可避免腋窝淋巴结摘除

2014-11-09

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Nature：同济大学参与发表三阴性乳腺癌全新结果

2014-08-16

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Ann Surg Oncol：大切缘手术不降低三阴性乳腺癌局部复发率

2014-03-20

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO 2014：gBRCA突变和家族史是三阴性乳腺癌pCR高的预测因素

2015-03-15

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）

2015-03-17

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

SABCS 2013：三阴性乳腺癌新辅助化疗获益

2014-06-09

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JCO：西妥昔单抗联合顺铂可改善三阴性乳腺癌患者生存

2013-09-24

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞

2013-09-12

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO 2013：三阴性乳腺癌患者中TNBC亚型可预测患者对治疗的应答率

2013-09-10

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

PLoS ONE：肿瘤周围组织存在抑制三阴性乳腺癌转移物质

2013-02-13

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征

2013-07-07

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

NEJM：新辅助化疗和贝伐单抗治疗HER2-阴性乳腺癌

2012-11-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌：探索与进展

2013-01-15

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

J. Exp. Med.：阻断CDK蛋白可导致三阴性乳腺癌萎缩

2012-12-23

科室
- - 订阅+
  - 更多科室
工具
服务